The experience gained with biosimilars has made it clear that copies of complex drugs are more challenging to produce and put on the market than generics. In the case of so-called nonbiological complex drugs (NBCDs), the complexity can arise either from a complex active substance or by other factors, such as formulation or route of delivery. Regulatory policies in the USA and the EU for the marketing of NBCD copies are reviewed, using glatiramer acetate copies as a case study. In the USA, they are approved and marketed as generics (although needing additional data), and so they are interchangeable with the originator. In the EU, they are managed with a hybrid application, and their interchangeability and substitution are established by individual member states.

Copies of nonbiological complex drugs: generic, hybrid or biosimilar? / P. Rocco, U.M. Musazzi, S. Franzè, P. Minghetti. - In: DRUG DISCOVERY TODAY. - ISSN 1359-6446. - 24:1(2019 Jan), pp. 250-255. [10.1016/j.drudis.2018.08.003]

Copies of nonbiological complex drugs: generic, hybrid or biosimilar?

P. Rocco
Primo
;
U.M. Musazzi
Secondo
;
S. Franzè
Penultimo
;
P. Minghetti
Ultimo
2019

Abstract

The experience gained with biosimilars has made it clear that copies of complex drugs are more challenging to produce and put on the market than generics. In the case of so-called nonbiological complex drugs (NBCDs), the complexity can arise either from a complex active substance or by other factors, such as formulation or route of delivery. Regulatory policies in the USA and the EU for the marketing of NBCD copies are reviewed, using glatiramer acetate copies as a case study. In the USA, they are approved and marketed as generics (although needing additional data), and so they are interchangeable with the originator. In the EU, they are managed with a hybrid application, and their interchangeability and substitution are established by individual member states.
Settore CHIM/09 - Farmaceutico Tecnologico Applicativo
4-ago-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
Manuscript_post_print.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 197.45 kB
Formato Adobe PDF
197.45 kB Adobe PDF Visualizza/Apri
1-s2.0-S1359644618300825-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 174.56 kB
Formato Adobe PDF
174.56 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/585989
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact